Search

Your search keyword '"Maurillo, Luca"' showing total 365 results
Start Over Author "Maurillo, Luca" Language english
365 results on '"Maurillo, Luca"'

1. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia

Author

Travaglini, Serena, Silvestrini, Giorgia, Attardi, Enrico, Fanciulli, Maurizio, Scalera, Stefano, Antonelli, Silvia, Maurillo, Luca, Palmieri, Raffaele, Divona, Mariadomenica, Ciuffreda, Ludovica, Savi, Arianna, Paterno, Giovangiacinto, Ottone, Tiziana, Barbieri, Caterina, Maciejewski, Jaroslaw P., Gurnari, Carmelo, Ciliberto, Gennaro, and Voso, Maria Teresa

Published
2024
Full Text
View/download PDF

3. MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients

Author

Catalano, Gianfranco, Zaza, Alessandra, Banella, Cristina, Pelosi, Elvira, Castelli, Germana, de Marinis, Elisabetta, Smigliani, Ariela, Travaglini, Serena, Ottone, Tiziana, Divona, Mariadomenica, Del Principe, Maria Ilaria, Buccisano, Francesco, Maurillo, Luca, Ammatuna, Emanuele, Testa, Ugo, Nervi, Clara, Venditti, Adriano, Voso, Maria Teresa, and Noguera, Nelida Ines

Published
2023
Full Text
View/download PDF

4. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia

Author

Paterno, Giovangiacinto, Palmieri, Raffaele, Tesei, Cristiano, Nunzi, Andrea, Ranucci, Giorgia, Mallegni, Flavia, Moretti, Federico, Meddi, Elisa, Tiravanti, Ilaria, Marinoni, Massimiliano, Page, Camilla, Fagiolo, Solaria, Buzzatti, Elisa, Secchi, Roberto, Gurnari, Carmelo, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, and Del Principe, Maria Ilaria

Published
2024
Full Text
View/download PDF

5. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Author

Pepe, Sara, Rossi, Elena, Trawinska, Malgorzata, Tatarelli, Caterina, Di Veroli, Ambra, Maurillo, Luca, Romano, Atelda, Crescenzi, Sabrina Leonetti, di Toritto, Tommaso Caravita, Tafuri, Agostino, Latagliata, Roberto, Scalzulli, Emilia, Andriani, Alessandro, De Stefano, Valerio, and Breccia, Massimo

Published
2022
Full Text
View/download PDF

7. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

Author

Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano

Published
2022
Full Text
View/download PDF

8. Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Author

Gurnari, Carmelo, Piciocchi, Alfonso, Soddu, Stefano, Bonanni, Fabrizio, Scalzulli, Emilia, Niscola, Pasquale, Di Veroli, Ambra, Piccioni, Anna Lina, Piedimonte, Monica, Maiorana, Gianluca, Salutari, Prassede, Cicconi, Laura, Santopietro, Michelina, Gumenyuk, Svitlana, Sarlo, Chiara, Fenu, Susanna, Tafuri, Agostino, Latagliata, Roberto, Fianchi, Luana, Criscuolo, Marianna, Maciejewski, Jaroslaw P., Maurillo, Luca, Buccisano, Francesco, Breccia, Massimo, and Voso, Maria Teresa

Published
2022
Full Text
View/download PDF

10. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Mazza, Patrizio, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Fabbiano, Francesco, Tafuri, Agostino, Chierichini, Anna, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Foà, Robin, Alati, Caterina, La Sala, Edoardo, Fazi, Paola, Vignetti, Marco, Maurillo, Luca, Buccisano, Francesco, Del Principe, Maria Ilaria, Irno-Consalvo, Maria, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Lo-Coco, Francesco, Arcese, William, and Amadori, Sergio

Published
2019
Full Text
View/download PDF

11. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

Author

Di Veroli, Ambra, Campagna, Alessia, De Muro, Marianna, Maurillo, Luca, Trawinska, Malgorzata Monika, LeonettiCrescenzi, Sabrina, Petriccione, Luca, Romano, Atelda, D’Addosio, Ada, Cenfra, Antonia, Montanaro, Marco, Felici, Stefano, Andriani, Alessandro, Carmosino, Ida, Niscola, Pasquale, Montefusco, Enrico, Breccia, Massimo, and Latagliata, Roberto

Published
2019
Full Text
View/download PDF

12. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Arena, Valentina, Palmieri, Raffaele, Filì, Carla, Carella, Angelo Michele, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Curti, Antonio, Luppi, Mario, Ingrosso, Claudia, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Mulè, Antonino, Tafuri, Agostino, Cudillo, Laura, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Trisolini, Silvia Maria, Alati, Caterina, La Sala, Edoardo, Maurillo, Luca, Del Principe, Maria Ilaria, Irno Consalvo, Maria Antonietta, Divona, Maria Domenica, Ottone, Tiziana, Cerretti, Raffaella, Sconocchia, Giuseppe, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, and Buccisano, Francesco

Published
2024
Full Text
View/download PDF

13. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Author

Schuurhuis, Gerrit J., Heuser, Michael, Freeman, Sylvie, Béné, Marie-Christine, Buccisano, Francesco, Cloos, Jacqueline, Grimwade, David, Haferlach, Torsten, Hills, Robert K., Hourigan, Christopher S., Jorgensen, Jeffrey L., Kern, Wolfgang, Lacombe, Francis, Maurillo, Luca, Preudhomme, Claude, van der Reijden, Bert A., Thiede, Christian, Venditti, Adriano, Vyas, Paresh, Wood, Brent L., Walter, Roland B., Döhner, Konstanze, Roboz, Gail J., and Ossenkoppele, Gert J.

Published
2018
Full Text
View/download PDF

15. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Author

Todisco, Elisabetta, Papayannidis, Cristina, Fracchiolla, Nicola, Petracci, Elisabetta, Zingaretti, Chiara, Vetro, Calogero, Martelli, Maria Paola, Zappasodi, Patrizia, Di Renzo, Nicola, Gallo, Susanna, Audisio, Ernesta, Griguolo, Davide, Cerchione, Claudio, Selleri, Carmine, Mattei, Daniele, Bernardi, Massimo, Fumagalli, Monica, Rizzuto, Giuliana, Facchini, Luca, Basilico, Claudia Maria, Manfra, Ilenia, Borlenghi, Erika, Cairoli, Roberto, Salutari, Prassede, Gottardi, Michele, Molteni, Alfredo, Martini, Vincenza, Lunghi, Monia, Fianchi, Luana, Cilloni, Daniela, Lanza, Francesco, Abruzzese, Elisabetta, Cascavilla, Nicola, Rivellini, Flavia, Ferrara, Felicetto, Maurillo, Luca, Nanni, Jacopo, Romano, Alessandra, Cardinali, Valeria, Gigli, Federica, Roncoroni, Elisa, Federico, Vincenzo, Marconi, Giovanni, Volpi, Roberta, Sciumè, Mariarita, Tarella, Corrado, Rossi, Giuseppe, Martinelli, Giovanni, Todisco, Elisabetta, Papayannidis, Cristina, Fracchiolla, Nicola, Petracci, Elisabetta, Zingaretti, Chiara, Vetro, Calogero, Martelli, Maria Paola, Zappasodi, Patrizia, Di Renzo, Nicola, Gallo, Susanna, Audisio, Ernesta, Griguolo, Davide, Cerchione, Claudio, Selleri, Carmine, Mattei, Daniele, Bernardi, Massimo, Fumagalli, Monica, Rizzuto, Giuliana, Facchini, Luca, Basilico, Claudia Maria, Manfra, Ilenia, Borlenghi, Erika, Cairoli, Roberto, Salutari, Prassede, Gottardi, Michele, Molteni, Alfredo, Martini, Vincenza, Lunghi, Monia, Fianchi, Luana, Cilloni, Daniela, Lanza, Francesco, Abruzzese, Elisabetta, Cascavilla, Nicola, Rivellini, Flavia, Ferrara, Felicetto, Maurillo, Luca, Nanni, Jacopo, Romano, Alessandra, Cardinali, Valeria, Gigli, Federica, Roncoroni, Elisa, Federico, Vincenzo, Marconi, Giovanni, Volpi, Roberta, Sciumè, Mariarita, Tarella, Corrado, Rossi, Giuseppe, Martinelli, Giovanni, Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, and Martinelli, G

Subjects
Cancer Research, hypomethylating agents, Oncology, hypomethylating agent, relapsed and refractory AML, venetoclax, real-life data, acute myeloid leukemia
Abstract

Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia. Methods: AVALON is a multicentric cohort study that was conducted in Italy on patients with AML who received venetoclax-based therapies from 2015 to 2020. The study was approved by the ethics committee of the participating institution and was conducted in accordance with the Declaration of Helsinki. The effectiveness and toxicity of venetoclax+HMA in 190 (43 newly diagnosed, 68 refractory, and 79 relapsed) patients with AML are reported here. Results: In the newly diagnosed AML, the overall response rate and survival confirmed the brilliant results demonstrated in VIALE-A. In the relapsed or refractory AML, the combination demonstrated a surprisingly complete remission rate (44.1% in refractory and 39.7% in relapsed evaluable patients) and conferred to treated patients a good expectation of survival. Toxicities were overall manageable, and most incidents occurred in the first 60days of therapy. Infections were confirmed as the most common nonhematologic adverse event. Conclusions: Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax+HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax+HMA effectiveness and toxicities in real life.

Published
2023

18. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study

Author

Buccisano, Francesco, Piccioni, Anna Lina, Nobile, Carolina, Criscuolo, Marianna, Niscola, Pasquale, Tatarelli, Caterina, Fianchi, Luana, Villivà, Nicoletta, Neri, Benedetta, Carmosino, Ida, Gumenyuk, Svitlana, Mancini, Stefano, Voso, Maria Teresa, Maurillo, Luca, Breccia, Massimo, Zini, Gina, Venditti, Adriano, Fenu, Susanna, Spiriti, Maria Antonietta Aloe, Latagliata, Roberto, and on behalf of GROM (Gruppo Romano Mielodisplasie)

Published
2016
Full Text
View/download PDF

20. Erratum:Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party (HemaSphere (2022) 6:1 (e676) DOI: 10.1097/HS9.0000000000000676)

Author

Tettero, Jesse M., Freeman, Sylvie D., Buecklein, Veit, Venditti, Adriano, Maurillo, Luca, Kern, Wolfgang, Walter, Roland B., Wood, Brent L., Roumier, Christophe, Philippe, Jan, Denys, Barbara, Jorgensen, Jeffrey L., Bene, Marie C., Lacombe, Francis, Plesa, Adriana, Guzman, Monica L., Wierzbowska, Agnieszka, Czyz, Anna, Ngai, Lok Lam, Schwarzer, Adrian, Bachas, Costa, Cloos, Jacqueline, Subklewe, Marion, Fuering-Buske, Michaela, Buccisano, Francesco, VU University medical center, Hematology laboratory, AII - Cancer immunology, and CCA - Imaging and biomarkers

Abstract

Since the publication of the article entitled Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party (HemaSphere. 2022;6(1):e676), the authors have requested a referencing correction. For Table 1, the correct references are 12-16. This has now been adjusted.

Published
2022

21. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems

Author

Buckstein, Rena, Balleari, Enrico, Wells, Richard, Santini, Valeria, Sanna, Alessandro, Salvetti, Chiara, Crisà, Elena, Allione, Bernardino, Danise, Paolo, Finelli, Carlo, Clavio, Marino, Poloni, Antonella, Salvi, Flavia, Cilloni, Daniela, Oliva, Esther Natalie, Musto, Pellegrino, Houston, Brett, Zhu, Nancy, Geddes, Michelle, Leitch, Heather, Leber, Brian, Sabloff, Mitchell, Nevill, Thomas J., Yee, Karen W., Storring, John M., Francis, Janika, Maurillo, Luca, Latagliata, Roberto, Spiriti, Maria Antonietta Aloe, Andriani, Alessandro, Piccioni, Anna Lina, Fianchi, Luana, Fenu, Susanna, Gumenyuk, Svitlana, and Buccisano, Francesco

Published
2017
Full Text
View/download PDF

24. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment

Author

Bo, Michele Dal, Del Principe, Maria Ilaria, Pozzo, Federico, Ragusa, Dario, Bulian, Pietro, Rossi, Davide, Capelli, Giovanni, Rossi, Francesca Maria, Niscola, Pasquale, Buccisano, Francesco, Bomben, Riccardo, Zucchetto, Antonella, Maurillo, Luca, de Fabritiis, Paolo, Amadori, Sergio, Gaidano, Gianluca, Gattei, Valter, and Del Poeta, Giovanni

Published
2014
Full Text
View/download PDF

25. High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma

Author

Del Principe, Maria Ilaria, Buccisano, Francesco, Cefalo, Mariagiovanna, Maurillo, Luca, Di Caprio, Luigi, Di Piazza, Fabio, Sarlo, Chiara, De Angelis, Gottardo, Irno Consalvo, Maria, Fraboni, Daniela, De Santis, Giovanna, Ditto, Concetta, Postorino, Massimiliano, Sconocchia, Giuseppe, Del Poeta, Giovanni, Amadori, Sergio, and Venditti, Adriano

Published
2014
Full Text
View/download PDF

26. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study

Author

Tatarelli, Caterina, Piccioni, Anna Lina, Maurillo, Luca, Naso, Virginia, Battistini, Roberta, D’Andrea, Mariella, Criscuolo, Marianna, Nobile, Carolina, Villivà, Nicoletta, Mancini, Stefano, Neri, Benedetta, Breccia, Massimo, Fenu, Susanna, Buccisano, Francesco, Voso, Maria Teresa, Latagliata, Roberto, and Aloe Spiriti, Maria Antonietta

Published
2014
Full Text
View/download PDF

27. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

Author

Latagliata, Roberto, Montagna, Chiara, Porrini, Raffaele, Di Veroli, Ambra, Leonetti, Sabrina Crescenzi, Niscola, Pasquale, Ciccone, Fabrizio, Spadea, Antonio, Breccia, Massimo, Maurillo, Luca, Rago, Angela, Spirito, Francesca, Cedrone, Michele, De Muro, Marianna, Montanaro, Marco, Andriani, Alessandro, Bagnato, Antonino, Montefusco, Enrico, and Alimena, Giuliana

Published
2016
Full Text
View/download PDF

28. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Author

Voso, Maria Teresa, Niscola, Pasquale, Piciocchi, Alfonso, Fianchi, Luana, Maurillo, Luca, Musto, Pellegrino, Pagano, Livio, Mansueto, Giovanna, Criscuolo, Marianna, Aloe-Spiriti, Maria Antonietta, Buccisano, Francesco, Venditti, Adriano, Tendas, Andrea, Piccioni, Anna Lina, Zini, Gina, Latagliata, Roberto, Filardi, Nunzio, Fragasso, Alberto, Fenu, Susanna, and Breccia, Massimo

Published
2016
Full Text
View/download PDF

29. Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.

Author

Meddi, Elisa, Savi, Arianna, Moretti, Federico, Mallegni, Flavia, Palmieri, Raffaele, Paterno, Giovangiacinto, Buzzatti, Elisa, Del Principe, Maria Ilaria, Buccisano, Francesco, Venditti, Adriano, and Maurillo, Luca

Subjects
ACUTE myeloid leukemia, CANCER remission, PROGNOSIS, DISEASE relapse, PATIENTS' attitudes
Abstract

In acute myeloid leukemia (AML) many patients experience relapse, despite the achievement of morphological complete remission; therefore, conventional morphologic criteria are currently considered inadequate for assessing the quality of the response after treatment. Quantification of measurable residual disease (MRD) has been established as a strong prognostic marker in AML and patients that test MRD negative have lower relapse rates and better survival than those who test positive. Different techniques, varying in their sensitivity and applicability to patients, are available for the measurement of MRD and their use as a guide for selecting the most optimal post-remission therapy is an area of active investigation. Although still controversial, MRD prognostic value promises to support drug development serving as a surrogate biomarker, potentially useful for accelerating the regulatory approval of new agents. In this review, we will critically examine the methods used to detect MRD and its potential role as a study endpoint. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients.

Author

Guarnera, Luca, Trotta, Gentiana Elena, Boldrini, Valentina, Cardillo, Lucia, Cerroni, Ilaria, Mezzanotte, Valeria, Pasqualone, Gianmario, Savi, Arianna, Borsellino, Beatrice, Buzzatti, Elisa, Palmieri, Raffaele, Paterno, Giovangiacinto, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, and Del Principe, Maria Ilaria

Subjects
MULTIDRUG resistance, ACUTE myeloid leukemia, CATHETER-related infections, HEMATOLOGIC malignancies, FEVER, COLONIZATION (Ecology)
Abstract

Background: Colonization by multidrug-resistant organisms (MDRO) is a frequent complication in hematologic departments, which puts patients at risk of life-threatening bacterial sepsis. Fever of unknown origin (FUO) is a condition related to the delivery of chemotherapy in hematologic malignancies, in which the use of antibiotics is debated. The incidence, risk factors, and influence on the outcome of these conditions in patients with acute myeloid leukemia (AML) are not clearly defined. Methods: We retrospectively analyzed 132 consecutive admissions of non-promyelocytic AML patients at the Hematology Unit of the University Tor Vergata in Rome between June 2019 and February 2022. MDRO swab-based screening was performed in all patients on the day of admission and once weekly after that. FUO was defined as fever with no evidence of infection. Results: Of 132 consecutive hospitalizations (69 AML patients), MDRO colonization was observed in 35 cases (26%) and resulted independently related to a previous MDRO colonization (p=0.001) and length of hospitalization (p=0.03). The colonization persistence rate in subsequent admissions was 64%. MDRO-related bloodstream infection was observed in 8 patients (23%) and correlated with grade III/IV mucositis (p=0.008) and length of hospitalization (p=0.02). FUO occurred in 68 cases (51%) and correlated with an absolute neutrophilic count <500µ/L at admission (0.04). Conclusion: In our experience, MDRO colonization is a frequent and difficult-to-eradicate condition that can arise at all stages of treatment. Prompt discharge of patients as soon as clinical conditions allow could limit the spread of MDRO. In addition, the appropriate use of antibiotics, especially in the case of FUO, and the contraction of hospitalization length, when feasible, are measures to tackle the further spread of MDRO. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.

Author

Palmieri, Raffaele, Paterno, Giovangiacinto, Mallegni, Flavia, Frenza, Federica, De Bernardis, Ilenia, Moretti, Federico, Meddi, Elisa, Ilaria Del Principe, Maria, Maurillo, Luca, Venditti, Adriano, and Buccisano, Francesco

Subjects
GENETIC profile, TUMORS, THERAPEUTICS, ACUTE myeloid leukemia
Abstract

Therapy-related myeloid neoplasms (t-MNs) encompass a specific sub-group of myeloid malignancies arising after exposure to radio/cytotoxic agents for the treatment of unrelated diseases. Such malignancies present unique features, including advanced age, high comorbidities burden, and unfavorable genetic profiles. All these features justify the need for a specific diagnostic workup and dedicated treatment algorithms. However, as new classification systems recognize the unique clinical characteristics exhibited by t-MN patients, how to assess fitness status in this clinical setting is largely unexplored. Optimizing fitness assessment would be crucial in the management of t-MN patients, considering that factors usually contributing to a worse or better outcome (like age, comorbidities, and treatment history) are patient-specific. In the absence of specific tools for fitness assessment in this peculiar category of AML, the aim of this review is to describe all those factors related to patient, treatment, and disease that allow planning treatments with an optimal risk/benefit ratio. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.

Author

Sconocchia, Giuseppe, Lanzilli, Giulia, Cesarini, Valeriana, Silvestris, Domenico A., Rezvani, Katayoun, Arriga, Roberto, Caratelli, Sara, Ken Chen, Jinzhuang Dou, Cenciarelli, Carlo, Toietta, Gabriele, Baldari, Silvia, Sconocchia, Tommaso, De Paolis, Francesca, Aureli, Anna, Iezzi, Giandomenica, Consalvo, Maria Irno, Buccisano, Francesco, del Principe, Maria I., and Maurillo, Luca

Published
2022
Full Text
View/download PDF

34. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

Author

Buccisano, Francesco, Maurillo, Luca, Spagnoli, Alessandra, Del Principe, Maria Ilaria, Fraboni, Daniela, Panetta, Paola, Ottone, Tiziana, Consalvo, Maria Irno, Lavorgna, Serena, Bulian, Pietro, Ammatuna, Emanuele, Angelini, Daniela F., Diamantini, Adamo, Campagna, Selenia, Ottaviani, Licia, Sarlo, Chiara, Gattei, Valter, Del Poeta, Giovanni, Arcese, William, Amadori, Sergio, Lo Coco, Francesco, and Venditti, Adriano

Published
2010
Full Text
View/download PDF

35. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

Author

Fianchi, Luana, Pagano, Livio, Piciocchi, Alfonso, Candoni, Anna, Gaidano, Gianluca, Breccia, Massimo, Criscuolo, Marianna, Specchia, Giorgina, Maria Pogliani, Enrico, Maurillo, Luca, Aloe-Spiriti, Maria Antonietta, Mecucci, Cristina, Niscola, Pasquale, Rossetti, Elena, Mansueto, Giovanna, Rondoni, Michela, Fozza, Claudio, Invernizzi, Rosangela, Spadea, Antonio, Fenu, Susanna, Buda, Gabriele, Gobbi, Marco, Fabiani, Emiliano, Sica, Simona, Hohaus, Stefan, Leone, Giuseppe, and Voso, Maria Teresa

Published
2015
Full Text
View/download PDF

36. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia

Author

Maurillo, Luca, Buccisano, Francesco, Piciocchi, Alfonso, Del Principe, Maria Ilaria, Sarlo, Chiara, Di Veroli, Ambra, Panetta, Paola, Irno-Consalvo, Maria, Nasso, Daniela, Ditto, Concetta, Refrigeri, Marco, De Angelis, Gottardo, Cerretti, Raffaella, Arcese, William, Sconocchia, Giuseppe, Lo-Coco, Francesco, Amadori, Sergio, and Venditti, Adriano

Published
2015
Full Text
View/download PDF

38. Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience.

Author

Paterno, Giovangiacinto, Palmieri, Raffaele, Forte, Vittorio, Del Prete, Valentina, Gurnari, Carmelo, Guarnera, Luca, Mallegni, Flavia, Pascale, Maria Rosaria, Buzzatti, Elisa, Mezzanotte, Valeria, Cerroni, Ilaria, Savi, Arianna, Buccisano, Francesco, Maurillo, Luca, Venditti, Adriano, and Del Principe, Maria Ilaria

Subjects
THROMBOEMBOLISM risk factors, THROMBOSIS, VEINS, WORLD health, ACQUISITION of data, RETROSPECTIVE studies, DISEASE incidence, RISK assessment, CANCER patients, DISEASE relapse, MEDICAL records, DESCRIPTIVE statistics, PLATELET count, SYMPTOMS, COMORBIDITY
Abstract

Simple Summary: The reported incidence of thrombotic events (TE) in non-promyelocytic acute myeloid leukemia (AML) patients varies in the literature from 2% to 13%. The aim of our retrospective study was to assess the incidence of TE in a real-word population of AML patients to determine the impact of TE on survival and to recognize risk factors for early venous thromboembolism (VTE). We observed a TE incidence of 14.6% among 300 patients with newly diagnosed AML. Arterial TE but not VTE was associated with a poorer OS. Furthermore, we observed a higher relapse rate among patients experiencing a VTE. We recognized platelets count >50 × 109/L, presence of comorbidities and a previous history of TE as risk factors for early VTE development. Accordingly, we proposed a score combining these factors that may help in implementing strategies to manage patients at higher risk of early thrombotic complications. Information regarding the incidence and the prognostic impact of thrombotic events (TE) in non-promyelocytic acute myeloid leukemia (AML) is sparse. Although several risk factors associated with an increased risk of TE development have been recognized, we still lack universally approved guidelines for identification and management of these complications. We retrospectively analyzed 300 consecutive patients with newly diagnosed AML. Reporting the incidence of venous TE (VTE) and arterial TE (ATE) was the primary endpoint. Secondarily, we evaluated baseline patient- and disease-related characteristics with a possible influence of VTE-occurrence probability. Finally, we evaluated the impact of TE on survival. Overall, the VTE incidence was 12.3% and ATE incidence was 2.3%. We identified three independent predictors associated with early-VTE: comorbidities (p = 0.006), platelets count >50 × 109/L (p = 0.006), and a previous history of VTE (p = 0.003). Assigning 1 point to each variable, we observed an overall cumulative incidence of VTE of 18.4% in the high-risk group (≥2 points) versus 6.4% in the low-risk group (0–1 point), log-rank = 0.002. Overall, ATE, but not VTE, was associated with poor prognosis (p < 0.001). In conclusion, TE incidence in AML patients is not negligible. We proposed an early-VTE risk score that could be useful for a proper management of VTE prophylaxis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.

Author

Molica, Matteo, Mazzone, Carla, Niscola, Pasquale, Carmosino, Ida, Di Veroli, Ambra, De Gregoris, Cinzia, Bonanni, Fabrizio, Perrone, Salvatore, Cenfra, Natalia, Fianchi, Luana, Piccioni, Anna Lina, Spadea, Antonio, Luzi, Giovanni, Mengarelli, Andrea, Cudillo, Laura, Maurillo, Luca, Pagano, Livio, Breccia, Massimo, Rigacci, Luigi, and De Fabritiis, Paolo

Subjects
THERAPEUTIC use of antimetabolites, THERAPEUTIC use of antineoplastic agents, RESEARCH, DRUG efficacy, CONFIDENCE intervals, MULTIVARIATE analysis, HEALTH outcome assessment, ACQUISITION of data, RETROSPECTIVE studies, EXPERIENCE, CANCER patients, RISK assessment, MEDICAL records, DESCRIPTIVE statistics, SURVIVAL analysis (Biometry), OVERALL survival, OLD age
Abstract

Simple Summary: Intensive induction strategies are rarely used for older patients in community on-cology practice, with comorbidities being the major cause of contraindication. We conducted a multicentric retrospective study to evaluate activity and safety in a real-life setting of hypomethylating drugs (HMAs) in patients older than 75 years with AML. In multivariate analysis, age (≥80), Charlson comorbidity index (≥3), creatinine clearance and the type of best response (≥PR) during treatment maintained independent significance in predicting survival. Furthermore, our data show that HMAs have similar efficacy compared to pivotal trials and are well tolerated in a setting of very elderly patients with several co-comorbidities. Elderly patients represent the most challenging and hard-to-treat patient population due to dismal characteristics of the disease, such as secondary-acute myeloid leukemia (AML), enrichment of unfavorable molecular genes (TP53) and comorbidities. We conducted a multicentric retrospective study to evaluate activity and safety in a real-life setting of hypomethylating drugs (HMAs) in patients older than 75 years with AML. Between September 2010 and December 2021, 220 patients were treated, 164 (74.5%) received AZAcitidine and 56 DECitabine; most patients (57.8%), received more than four cycles of HMAs. The best response obtained was CR in 51 patients (23.2%), PR in 23 (10.5%) and SD in 45 (20.5%); overall transfusion independence was obtained in 47 patients (34%), after a median of 3.5 months. The median OS (mOs) was 8 months (95% CI 5.9–10.2), with 1- and 2-years OS of 39.4% (95% CI 32.7–46) and 17.4% (95% CI 11.7–23.1), respectively; similar mOS was observed according to HMA treatment (AZA 8.3 vs. DEC 7.8 months, p = 0.810). A subset of 57 long survivors (44 in AZA group and 13 in DEC group) received at least 12 cycles of HMAs, their mOS was 24.3 months. In multivariate analysis, age (≥80), Charlson comorbidity index (≥3), creatinine clearance and the type of best response (≥PR) during treatment maintained independent significance in predicting survival. Infectious complications, most frequently pneumonia (35) and septic shock (12), were lethal in 49 patients (22.2%). Our data show that HMAs have similar efficacy compared to pivotal trials and are well tolerated in a setting of very elderly patients with several co-comorbidities. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma.

Author

Pasqualone, Gianmario, Buzzatti, Elisa, Palmieri, Raffaele, Savi, Arianna, Pascale, Maria Rosaria, Borsellino, Beatrice, Guarnera, Luca, Buccisano, Francesco, Voso, Maria Teresa, Maurillo, Luca, Sconocchia, Giuseppe, Venditti, Adriano, and Del Principe, Maria Ilaria

Subjects
MYELOID sarcoma, EXTRAMEDULLARY diseases, BLOOD transfusion, ACUTE myeloid leukemia, MYCOSES, BLAST injuries, FEBRILE neutropenia
Abstract

Myeloid sarcoma is a hematologic malignancy consisting of extramedullary tissue involvement by myeloid blasts, usually considered as acute myeloid leukemia and treated accordingly. The disease itself, together with chemotherapy and disease-associated factors, may have an impact in increasing the risk of developing severe and frequently life-threatening infections. Herein, we describe the case of a patient with a right breast skin lesion, histologically diagnosed myeloid sarcoma, who developed a severe disseminated fungal infection by Saprochaete clavata (Magnusiomyces clavatus), during the first consolidation course of chemotherapy. Despite maximum antifungal therapy, the infection progressed and the fungus continued to be isolated until granulocyte transfusion therapy was initiated. Our experience suggests that patients with profound and long-lasting neutropenia could benefit from granulocyte transfusions as additional therapy in severe fungal infections resistant to broad-spectrum antimicrobial therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Author

Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, and Todisco, Elisabetta

Published
2023
Full Text
View/download PDF

42. Lifestyle Behaviors and Health-Related Quality of Life in Long-Term Survivors of Acute Myeloid Leukemia: An International Survivorship Study By the Gimema, EORTC Quality of Life and Leukemia Groups

Author

Efficace, Fabio, Cannella, Laura, Thomas, Xavier, Yuksel, Meltem Kurt, Trisolini, Silvia Maria, Saveria, Capria, Brini, Alberto, Audisio, Ernesta, Maurillo, Luca, Lemoli, Roberto Massimo, Imovilli, Annalisa, Panovska Stavridis, Irina, Quattrone, Martina, Ciccone, Maria, Filardi, Nunzio, Fracchiolla, Nicola, Vallisa, Daniele, Crugnola, Monica, Melillo, Lorella Maria Antonia, Skerget, Matevz, Vignetti, Marco, and Baron, Frederic

Published
2023
Full Text
View/download PDF

43. Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Author

Venditti, Adriano, Piciocchi, Alfonso, Soddu, Stefano, Frigeni, Marco, Palmieri, Raffaele, Borlenghi, Erika, Fracchiolla, Nicola, Martelli, Maria Paola, Audisio, Ernesta, Gianfaldoni, Giacomo, Vetro, Calogero, di Rienzo, Nicola, Esposito, Daniela, Di Veroli, Ambra, Selleri, Carmine, Gigli, Federica, Curti, Antonio, Mulè, Antonino, Califano, Catello, Bigliardi, Sara, Breccia, Massimo, Fozza, Claudio, Bocchia, Monica, Lico, Albana, Simonetti, Federico, Pierdomenico, Elisabetta, Buccisano, Francesco, Del Principe, Maria Ilaria, Maurillo, Luca, Fazi, Paola, Vignetti, Marco, Ferrara, Felicetto, Cairoli, Roberto, Rossi, Giuseppe, and Rambaldi, Alessandro

Published
2023
Full Text
View/download PDF

45. Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms.

Author

Buzzatti, Elisa, Paterno, Giovangiacinto, Palmieri, Raffaele, Esposito, Fabiana, Pascale, Maria Rosaria, Mallegni, Flavia, Guarnera, Luca, Pasqualone, Gianmario, Irno Consalvo, Maria Antonietta, Fraboni, Daniela, Moretti, Federico, Savi, Arianna, Borsellino, Beatrice, Maurillo, Luca, Buccisano, Francesco, Sconocchia, Giuseppe, Venditti, Adriano, and Del Principe, Maria Ilaria

Subjects
CENTRAL nervous system, DENDRITIC cells, TUMORS, OCCULTISM, MENINGEAL cancer
Abstract

Central nervous system (CNS) involvement worsens the prognosis of hematologic neoplasms since cerebrospinal fluid (CSF) represents a sanctuary for malignant cells. Thus, it is evident that without the use of FCM we would have missed 17% and 40% of patients with CNS involvement at diagnosis and relapse respectively. Two patients (40%), who were not screened at diagnosis for CNS disease, resulted at relapse CC SP - sp /FCM SP + sp (15 and 40 events) (Table 1). [Extracted from the article]

Published
2022
Full Text
View/download PDF

48. CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.

Author

Palmieri, Raffaele, Buccisano, Francesco, Arena, Valentina, Irno Consalvo, Maria Antonietta, Piciocchi, Alfonso, Maurillo, Luca, DelPrincipe, Maria Ilaria, Di Veroli, Ambra, Paterno, Giovangiacinto, Conti, Consuelo, Fraboni, Daniela, Voso, Maria Teresa, Arcese, William, and Venditti, Adriano

Subjects
ACUTE myeloid leukemia, PRELEUKEMIA, STEM cells, FLOW cytometry, CD34 antigen, BIOMARKERS
Abstract

The absence of measurable residual disease (MRD) in morphologic complete remission (CR) represents a favorable prognosticator in acute myeloid leukemia (AML) [[1]]. At the diagnostic evaluation, patients were defined as LSCs negative (LSC-0) in case of undetectable LSCs count, LSC SP low sp and LSC SP high sp when LSCs were detected below or above a threshold of 0.03%, respectively [[4]]. Indeed, patients with a high LSC burden at diagnosis have an unfavorable outcome unless LSCs are cleared by chemotherapy. [Extracted from the article]

Published
2022
Full Text
View/download PDF

49. In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia.

Author

Buzzatti, Elisa, Forghieri, Fabio, Paterno, Giovangiacinto, Marchesi, Francesco, Sarlo, Chiara, Giglio, Fabio, Fracchiolla, Nicola, Sciumè, Mariarita, Palmieri, Raffaele, Esposito, Fabiana, Guarnera, Luca, Mercante, Lisa, Pascale, Maria Rosaria, Mallegni, Flavia, Savi, Arianna, Forte, Vittorio, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, and Del Principe, Maria Ilaria

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, STEROID drugs, LIVER function tests, ASPARAGINASE
Abstract

Hypofibrinogenemia (HF) in adult acute lymphoblastic leukemia (ALL) of B lineage is uncommon and mostly associated with asparaginase (ASP) delivery. Since we noticed a significant reduction in fibrinogen (FBG) plasma levels even before the first ASP dose, we aim to assess the levels of FBG during induction treatment and explore if the FBG fall correlated with therapies other than asparaginase and/or specific leukemia biological features. We retrospectively analyzed FBG levels in 115 patients with B-ALL. In 74 (64%) out of 115 patients FBG decline occurred during the steroid prephase. In univariate analysis, such a steroid-related HF was significantly associated with BCR-ABL1 rearrangement (p = 0.00158). None of those experiencing HF had significant modifications of liver function tests during induction treatment. Our retrospective study suggests that in B-ALL, steroid therapy can also induce HF and that such an event is preferentially observed in patients carrying BCR-ABL1 rearrangements. The pathogenesis of this phenomenon is still unclear. We attempt to explain it by applying the International Society of Thrombosis and Hemostasis-Disseminated Intravascular Coagulation score (ISTH-DIC score); nonetheless additional studies are needed to clarify further the mechanisms of HF in this subset of patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results